Who's leading Australia's drug charge?

With 10 applications on the TGA’s review list, AstraZeneca is at the forefront of bringing new therapies to Australia, followed by Novartis with eight.

To see the whole article please log in.

Tiffany Walker

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here